Decreased expression of microRNA-148a predicts poor prognosis in ovarian cancer and associates with tumor growth and metastasis

ObjectiveMicroRNA-148a (MiR-148a) had been reported to take part in some cancer progresses, but its clinical significance in ovarian cancer had been rarely reported. The purpose of this study was to evaluate the prognostic value of miR-148a as well as its roles in ovarian cancer progression.MethodsRelative expression of miR-148a in the plasma specimens of ovarian cancer patients was detected by qRT-PCR. Chi-square test was used to analyze the relationship between miR-148a expression and clinical characteristics. The overall survival was analyzed by Kaplan-Meier method and Cox regression analysis was used to evaluate the prognostic value of miR-148a. In addition, the ovarian cancer cell line SKOV-3 was separately transfected with pcDNA3-microRNA-148a over-expression vector and pcDNA3 empty vector to detect the functional roles of miR-148a in ovarian cancer progression.ResultsDecreased level of plasma miR-148a was observed in ovarian cancer patients compared with healthy controls. The expression level was associated with histopathologic grade, TNM stage and lymph node metastasis (P < 0.05 for all). Besides, patients with high level of miR-148a had a longer survival time than those with low level (40.3 months vs 31.6 months, log rank test, P = 0.002). Cox regression analysis indicated that miR-148a might be a potential biomarker for ovarian cancer prognosis (HR = 1.699, 95%CI = 1.175-2.456, P = 0.005). Moreover, cell experiments confirmed that miR-148a could inhibit proliferation, migration and invasion of ovarian cancer cells.ConclusionMiR-148a may be a potential prognostic factor for ovarian cancer and it can suppress tumor progression.     

Vascular endothelial growth factor and oxidative damage in cancer

OBJECTIVES: VEGF may be an indicator for the angiogenic potential of a tumor and stimulates NO which plays complex roles in cancer. In our study, we investigated the levels of MDA, NO and VEGF in the plasma of various types cancer patients (untreated, yet). DESIGN AND METHODS: The level of VEGF was determined by using ELISA. Plasma MDA, NO and VEGF levels were measured in 45 patients with various cancer types and in 21 healthy subjects. RESULTS: Plasma MDA and VEGF levels were significantly higher than those of the healthy subjects (p < 0,0001). NO levels of the patients were significantly lower vs. the healthy subjects (p < 0,001). CONCLUSIONS: Increased plasma VEGF and MDA concentrations and decreased plasma NO levels have been found in patients with various types of human cancer. Howewer, the prognostic and clinical significance of plasma VEGF in cancer patients is unknown.     

循环血浆VEGF IL-8水平与胃癌关系研究

目的探讨胃癌患者循环血管内皮生长因子 (VEGF)和白细胞介素-8(IL-8)水平的变化及其与胃癌临床病理学特征的关系. 方法应用酶联免疫吸附法 (ELISA)测定47例胃癌患者循环血浆VEGF、IL-8浓度,结合临床病理学资料进行分析. 结果胃癌患者循环血浆VEGF浓度为(65.12±29.53)pg/ml,显著高于正常对照组(32.97±9.79)pg/ml (P<0.01);IL-8浓度为(3.01±0.68)pg/ml,与对照组比较,差异无显著性意义(P>0.05).肿瘤浸润深度超过肌层,伴有淋巴结转移、血管浸润者,其循环血浆VEGF明显升高(P<0.05或P<0.01).循环血浆VEGF、IL-8之间呈弱正相关(r=0.433). 结论循环血浆VEGF水平与胃癌浸润、转移等有关.循环VEGF、IL-8之间有一定的相关性,联合检测循环血浆VEGF、IL-8对胃癌的诊断、疗效判断等有一定的价值.     

Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients

Objective. Vascular endothelial growth factor (VEGF) promotes normal and pathological angiogenesis. VEGF is a chemotactic factor for macrophages and vascular smooth muscle cells, and induces synthesis of metalloproteinases and adhesion molecules. VEGF expression is regulated by hypoxia, cytokines, oncogenes, and oxidized low‐density lipoprotein (LDL). The purpose of this study was to determine the relationship between levels of lipid parameters and VEGF, to investigate whether pravastatin treatment influences VEGF serum concentrations, and to examine the relationship between VEGF and the variations in post‐treatment lipid and inflammatory parameters. Material and methods. Eighteen patients aged 48±6.8 years with total cholesterol (TC) >6.1?mmol/L comprised the hypercholesterolemic group. The controls included 12 individuals aged 50±7.4 years with TC <5.1?mmol/L. TC, high‐density lipoprotein cholesterol (HDLC), triglycerides, LDLC, C‐reactive protein (CRP), and VEGF were determined in both groups at baseline, and in the hypercholesterolemic group after 4 months of treatment with 20?mg/day pravastatin. Results. A significant correlation was observed between concentrations of VEGF and TC, LDLC and TG, and a significant difference in VEGF concentration was observed between the control group (mean 142?ng/L) and the hypercholesterolemic group (mean 272.9?ng/L). A significant decrease was observed in TC (14.7 %), LDLC (21.5 %), CRP (22.7 %), and VEGF (14.8 %) after 4 months of treatment with pravastatin. Conclusions. A relationship was found between serum levels of VEGF and most atherogenic lipoproteins. In patients with hypercholesterolemia treated with pravastatin, a reduction in VEGF and CRP was seen in addition to lipid decreases.     

Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors

An imbalance between pro-angiogenic and anti-angiogenic factors is hypothesized in the pathogenesis of ovarian cystic disease. The aim of the following study was to explore the possible role of free vascular endothelial growth factor receptor 1 (sVEGFR-1), a soluble regulator of vascular endothelial growth factor (VEGF) action, in ovarian cystoadenoma, endometriomata and cystoadenocarcinoma. Forty-eight women, of whom fourteen had ovarian serous cysts, twenty-eight had stage III-IV ovarian endometriomata, and six had stage IIIB-IIIC ovarian carcinoma, were included. Sampling of serum, peritoneal and ovarian cystic fluids and of tumor tissue was performed before, during and following surgery, respectively. Levels of VEGF and sVEGFR-1 were measured in serum, peritoneal and cystic fluid. VEGF and sVEGFR-1 expression was evaluated in tumor tissue. There were no differences in serum VEGF and sVEGFR-1 levels nor in VEGF/VEGFR-1 ratio between study groups. Peritoneal fluid VEGF levels were higher in cystoadenocarcinoma patients than in endometriosis and in cystoadenoma patients, while sVEGFR-1 peritoneal fluid concentrations were significantly higher only in endometriosis-affected women. VEGF/VEGFR-1 ratio was highest in the peritoneal fluid of cancer patients with respect to the other two groups of women. Cystic fluid VEGF and VEGFR-1 concentrations were higher in endometriomata and in cystoadenocarcinomas than in cystadenomas but the VEGF/VEGFR-1 ratio was highest in cancer patients. Western blot evidenced a marked expression of VEGF and soluble VEGFR-1 in endometriosis tissue with respect to benign cyst tissue but a lower expression of both molecules, contrary to that expected, in cancer tissue. In conclusion, all in all, our data indicate that an excess of local VEGF with respect to its soluble receptor VEGFR-1 may be a key factor in the onset and maintenance of pathological neo-angiogenesis in ovarian cyst formation.     

Vascular endothelial growth factor in thyroid cyst fluids

BACKGROUND: The pathogenesis of cystic thyroid nodules is incompletely understood. Based on the assumption that vascular endothelial growth factor (VEGF) may play an important role in the pathogenesis of thyroid cyst fluid, we investigated the VEGF concentration in cyst fluids of thyroid lesions. DESIGN: Cyst fluids from 24 patients (age 31-84 years) were obtained using ultrasound-guided fine-needle aspiration. The patients' cystic thyroid nodules were of different origins. METHODS: Thyroid and cyst volumes were determined using high-resolution ultrasonography. VEGF concentrations were determined using a solid-phase enzyme-linked immunosorbent assay (ELISA). RESULTS: Differing elevated VEGF concentrations were demonstrated in cyst fluids of thyroid nodules of varied origins. The VEGF concentration in cyst fluid of patients with adenomatous goiter was significantly higher (P < 0.05) than that in thyroid nodules with cystic degeneration. The highest level of VEGF was found in bloody cyst fluid when compared with levels in other cyst fluids (P < 0.05). Interestingly, there was significant correlation (P < 0.01) between thyroid volume and VEGF concentration in cyst fluid, but no significant correlation (P = 0.20) between cyst volume and VEGF concentration. CONCLUSION: Significantly increased VEGF concentrations were found in bloody cyst fluid and in cyst fluid of thyroid adenomatous goiter, compared with VEGF concentrations in degenerative thyroid cysts. Our results suggest that VEGF may play an important role in the pathogenesis of thyroid cyst fluid.     

慢性阻塞性肺疾病诱导痰炎症细胞和白细胞介素-8的检测及意义

目的探讨慢性阻塞性肺疾病(COPD)稳定期患者气道炎症特征,白细胞介素8(IL8)在COPD发病机制中的作用。方法采用酶联免疫吸附法(ELISA)检测COPD稳定期患者18例和健康对照组11例痰中的IL8水平,手工检测诱导痰中炎症细胞总数(TCC)及其分类计数。结果COPD组痰中TCC和嗜中性粒细胞(PMN)计数高于健康对照组,差异有统计学意义(P<0.01);PMN占细胞总数的百分比(PMN%)高于对照组,而巨噬细胞占细胞总数的百分比(巨噬细胞%)低于对照组,差异有统计学意义(P<0.05)。COPD组痰中IL8浓度为(5.216±2.914)μg/L,对照组为(2.862±2.511)μg/L,差异有统计学意义(P<0.05)。结论COPD气道炎症是以中性粒细胞浸润为主,IL8在COPD的气道炎症及气道阻塞中均起重要作用,检测痰IL8水平能很好反映COPD气道炎症情况。     

严重肺挫伤患者冯·维勒布兰德因子,白介素8的动态变化及其意义

目的 通过检测严重肺挫伤患者血中冯·维勒布兰德因子(vWF),白介素8在受伤后不同时点的含量,揭示其动态变化规律及其临床价值.方法 将63例严重肺挫伤患者分成ARDS组和非ARDS组、生存组和死亡组、ISS评分<20分和ISS评分≥20分组,并引入正常对照组,使用ELISA法分别检测伤后24 h内、第3天、第5天、第7天时的血浆vWF和血清IL-8水平,观察其动态规律,并进行相关因素分析.结果 严重肺挫伤患者在各时点,血浆vWF和血清IL-8均高于正常对照组.严重肺挫伤并发ARDS组血浆vWF含量各时点逐渐升高,ARDS组在第5天、第7天血浆vWF含量显著高于非ARDS组(P<0.05).血清IL-8含量在第5天达到高峰后开始下降,两组之间在各时点差异具有统计学意义(P<0.05);死亡组血浆vWF与血清IL-8含量均显著高于生存组(P<0.05);ISS评分≥20分组血浆vWF和血清IL-8水平均在第5天达到高峰后开始回落,ISS评分<20分组在第3天达到高峰后回落.血浆vWF含量与血小板计数呈正相关,与氧合指数呈负相关.血清IL-8含量与白细胞计数、ISS评分呈正相关,与氧合指数呈负相关.结论 严重肺挫伤患者血中vWF和IL-8含量呈动态变化,反映了肺损伤的程度,并可以作为严重肺挫伤后并发ARDS的预测及预后判断指标.

Abstract：

Objective To study the clinical changes of von Willebrand factor( vWF) and interleukin-8 (IL-8) in patients with severe pulmonary contusion. Methods Sixty-three patients with severe pulmonary contusion were divided into three different classifications for the sake of comparison in different respects, namely (1) severe pulmonary contusion with ARDS group and severe pulmonary contusion without ARDS group, (2) survival group and non-survival group, and (3) ISS score <20 group and ISS scored 20 group. In addition, the normal control group was set up. The levels of plasma vWF and serum IL-8 were respectively detected by double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) within 24 hours of injury and 1,3,5 and 7days after injury. The regularity of their changes was observed and the correlation factors were analyzed from the data. Results Compared with normal controls, the concentrations of plasma vWF and serum IL-8 were significantly increased in patients with severe pulmonary contusion in all intervals of detection. The concentrations of plasma vWF escalated gradually in severe pulmonary contusion with ARDS, and reached significantly higher levels in 5 days and 7 days after injury compared with those without ARDS group (P <0. 05). The increase in concentrations of serum IL-8 peaked in 5day after injury, and then declined. The levels of serum IL-8 were higher in patients with severe pulmonary contusion with ARDS group than those in this kind of patients without ARDS group. The levels of plasma vWF and serum IL-8 were higher in non - survival group than those in survival group (P < 0.05). The increase in levels of plasma vWF and serum IL-8 peaked and then declined in 5 days in ISS score 3:20 group, whereas it peaked and declined in 3 days after injury in ISS score < 20 group. The level of plasma vWF was positively correlated with platelets and negatively correlated with oxygenation index. The levels of serum IL-8 was positively correlated with white blood cell count and ISS score, and negatively correlated with oxygenation index. Conclusions The levels of plasma vWF and serum IL-8 were increased in patients with severe pulmonary contusion, reflecting the severity of pulmonary injury. The levels of plasma vWF and serum IL-8 were the sensitive markers for evaluating the severity of pulmonary injury and the prognosis of ARDS caused by severe pulmonary contusion.     

Up-regulated microRNA-155 expression is associated with poor prognosis in cervical cancer patients

BackgroundMicroRNAs (miRNAs) play important roles in tumor development and progression. The purposes of the study was to investigate the role of miR-155 in cervical cancer.MethodsQuantitative real-time RT-PCR (qRT-PCR) was performed to examine miR-155 expression in cervical cancer tissues and adjacent non-cancerous tissues. The association with overall survival of patients was analyzed by Kaplan-Meier survival analysis. Small interfering RNA (siRNA) was used to suppress miR-155 expression in cervical cancer cells. In vitro assays were performed to further explore the biological functions of miR-155 in cervical cancer.ResultsWe found that miR-155 expression was markedly up-regulated in cervical cancer tissues and correlated with FIGO stage, lymph nodes metastasis, vascular invasion and HPV. Patients with high miR-155 expression level had poorer overall survival than those with low miR-155 expression. Furthermore, multivariate Cox regression analysis suggested that increased miR-155 was an independent prognostic indicator for cervical cancer (P = 0.007; HR = 2.320; 95%CI: 1.259–4.276). Moreover, knockdown of miR-155 was demonstrated to inhibit cell proliferation, migration, and invasion in vitro.ConclusionOur study presents that miR-155 is a novel molecule involved in cervical cancer progression, which provide a potential prognostic biomarker and therapeutic target.     

PLK1和P53蛋白在卵巢上皮性癌中的表达及其意义

目的检测POLO样蛋白激酶1(PLK1)和P53蛋白在卵巢上皮性癌中的表达,探讨其与患者预后的关系。方法采用免疫组织化学SP法检测20例正常卵巢组织、19例卵巢良性上皮性肿瘤组织和52例卵巢上皮性癌组织中PLK1和P53蛋白的表达情况,分析其与卵巢癌临床病理指标的关系及二者在卵巢癌组织中表达的相关性,单因素和多因素Logistic回归分析影响卵巢癌患者预后的危险因素,Kaplan-Meier法分析PLK1和P53表达与卵巢癌患者预后的关系。结果 PLK1和P53在卵巢上皮性癌组织中的表达分别为38.5%和67.3%,显著高于良性肿瘤和正常卵巢组织(P<0.05)。在卵巢上皮性癌中,PLK1和P53异常高表达与临床分期和组织分化相关,临床分期越晚、组织分化越差的癌组织中PLK1和P53蛋白表达越高(P<0.05);PLK1蛋白的表达与P53蛋白的表达呈负相关(r=-0.629,P=0.000)。单因素Logistic回归分析显示PLK1、P53、临床分期、组织分化和淋巴结转移是影响卵巢癌患者预后的因素,多因素Logistic回归分析显示仅PLK1是影响卵巢癌患者预后的独立因素(OR=2.288,P=0.025,95%CI:0.105⁵0.050)。与其他患者相比,PLK1表达阳性同时P53表达阳性的卵巢癌患者,生存期最短(?2=17.246,P=0.037)。结论 PLK1和P53共同参与了卵巢癌的发生发展,PLK1可作为判断卵巢癌患者预后的标志物。     

白细胞介素-2联合紫杉醇及卡铂治疗晚期卵巢癌疗效观察

目的 观察白细胞介素-2（IL-2）与紫杉醇、卡铂联合治疗晚期卵巢癌的近期疗效及不良反应.方法 对29例初治或复发的晚期卵巢癌患者使用IL-2联合紫杉醇、卡铂化疗方案进行治疗.IL-2 2500 IU静脉滴注,第1天;紫杉醇175 mg/m2,静脉滴注3h,第2天,卡铂曲线下面积=5静脉滴注,第2天.用紫杉醇之前常规进行预防性抗过敏处理.3周为1个周期,至少化疗3个周期,3个周期后评定疗效及不良反应.结果 29例均可评价疗效,有效率为62.07％（18/29）,其中完全缓解3例（10.34％）,部分缓解15例（51.72％）,稳定9例（31.03％）,进展2例（6.89％）.主要不良反应为恶心、呕吐、腹泻腹痛、中性粒细胞减少、乙酰胆碱综合征等,多为1～2级.结论 IL-2联合紫杉醇、卡铂是治疗晚期卵巢癌的有效方案,且不良反应可耐受,值得临床进一步研究.     

Lymphocyte and macrophage infiltration in omental metastases indicates poor prognosis in advance stage epithelial ovarian cancer

ObjectiveTo investigate the prognostic value of immune cells within omental metastases originating from advanced epithelial ovarian cancer (EOC).MethodsWe performed immunohistochemical analysis to determine the levels of CD4+/CD8+ tumor-infiltrating lymphocytes (TILs) and CD68+ tumor-associated microphages (TAMs) in omental specimens from 100 patients with advanced EOC. Significant prognostic factors, including immune cells and clinical parameters, were assessed by Kaplan–Meier survival analysis and Cox models.ResultsCox regression analysis showed that elevated levels of CD68+ TAMs and intra-islet CD4+ TILs in omental metastases were the main risk factors associated with worse survival outcomes for advanced EOC. Moreover, the survival analysis of relationships between omental immune cells and favorable clinical predictors revealed additional prognostic stratification information.ConclusionOmental immune cells (TAMs and TILs) provide alternative prognostic factors in advanced EOC. In contrast to markers of the EOC tumor microenvironment at the primary site, elevated CD68+ TAMs and intra-islet CD4+ TILs in omental metastases serve as negative prognostic markers in advanced EOC and imply an unfavorable outcome.     

抗卵巢上皮癌单克隆抗体的制备和鉴定

以人的浆液性卵巢上皮癌细胞系ＨＯ－８９１０为抗原，制备分泌抗卵巢癌单克隆抗体的杂交瘤，经间接免疫荧光组化鉴定证实。制备的单克隆抗体ＯＣ１Ｃ３与ＨＯ－８９１０呈强阳性反应，与其他肿细胞系则无反应或反应极弱。在冰冻切片中，单克隆抗体ＯＣ１Ｃ３与卵巢恶性肿瘤呈强阳性反应（７／８），与绒癌有部分交叉反应（１／２），与正常卵巢和胚胎组织无反应。结果表明ＯＣ１Ｃ３是卵巢恶性肿瘤的一种特异性抗原的单克隆抗体。为     

胃癌患者多层螺旋 CT 灌注参数与血清血管内皮生长因子关系的研究

目的：探讨不同分期胃癌患者多层螺旋 CT 灌注参数与血清血管内皮生长因子之间的关系。方法依据TNM 分期和病理分期,选择我院2011年10月至2012年10月收治的胃癌患者67例,分为胃癌Ⅰ-Ⅱ期患者和Ⅲ-Ⅳ期患者两组,采用 Toshiba Actvion16螺旋 CT 仪和 Stellant 高压注射器进行螺旋 CT 灌注扫描,并使用胰腺灌注软件处理数据。比较两组患者的灌注参数（血容量 BF、血流量 BS、平均通过时间 MTT 和渗透性表面容积 PS）、Ⅰ-Ⅱ期患者和Ⅲ-Ⅳ期患者血清血管内皮生长因子（VEGF）水平,采用 person 相关分析研究灌注参数与血清 VEGF 的相关性。结果胃癌Ⅲ-Ⅳ期患者灌注参数 BF 和 PS 高于胃癌Ⅰ-Ⅱ期患者,存在统计学差异（P ＜0．05）,但两组灌注参数 BV、MTT 之间无统计学差异（P ＞0．05）;胃癌Ⅰ-Ⅱ期患者与Ⅲ-Ⅳ期患者血清 VEGF 水平存在显著性差异（P ＜0．01）。胃癌Ⅰ-Ⅱ期患者与Ⅲ-Ⅳ期患者血清 VEGF 值与灌注参数 BF、PS 之间相关性显著,尤其是 PS,相关性系数分别为0.635和0．715,P 值均为0．001。结论多层螺旋 CT 灌注参数 PF、PS 对胃癌分期具有很大的应用价值,能为临床诊治提供参考。     

Overexpression of Ubiquilin4 is associated with poor prognosis in patients with cervical cancer

BACKGROUNDUbiquilins (UBQLNs) are important factors for cell proteostasis maintenance. UBQLNs are involved in the modulation of the cell cycle, as well as in apoptosis, membrane receptors regulation, DNA repair, epithelial-mesenchymal transition, and miRNA activities. They also affect the selection of double-strand break repair pathways. Abnormal UBQLNs expression can lead to many diseases, including cancer. Studies have found that the expression of Ubiquilin4 (UBQLN4) is associated with the development of several tumor types. However, the association between UBQLN4 and cervical cancer has not been examined yet.AIMTo investigate the expression of UBQLN4 in cervical cancer and to evaluate its correlation with disease prognosis.METHODSImmunohistochemistry was performed to examine the expression of UBQLN4 in 117 cervical cancer tissues and 32 matching pericervical tissues. Paired t-test (two-tailed) was used to compare the differences between groups. We collected patients’ clinical characteristics, including age, histological grade, pathologic type, lymph node metastasis, and FIGO stage (2018) and compared them by chi-square test. All patients were followed for 5.5 to 6.8 years. Kaplan-Meier method and log-rank test were used to compare the differences in the overall survival (OS) and progression-free survival (PFS) among the different groups.RESULTSOverexpression of UBQLN4 was observed in 70.9% (83/117) of all cervical cancer tissues and in 15.6% (5/32) of the paired parauterine tissues. The expression of UBQLN4 was associated with lymph node metastasis, poor differentiation, and advanced stage, but the difference was not significant. Kaplan-Meier and log-rank test results suggested the high expression of UBQLN4 was associated with short OS and PFS. Regardless of UBQLN4 expression, the patient age and FIGO stage were also associated with disease prognosis. The statistically significant variables obtained from univariate the Kaplan-Meier analysis were subjected to Cox multivariate survival regression analysis, which showed that, in addition to the FIGO stage and age, UBQLN4 was also an independent prognostic marker for OS and PFS (P = 0.011 and P = 0.024, respectively).CONCLUSIONThe overexpression of UBQLN4 was associated with poor prognosis in cervical cancer. Our study proposed a novel prognostic factor and improved the existing understanding of the pathogenesis of cervical cancer.     

卵巢癌患者创伤后成长及相关因素分析

目的 了解卵巢癌患者创伤后成长现状并分析其影响因素。方法 采用方便抽样法,选取2018年5—12月在湖南省人民医院乳甲外科、湖南师范大学附属解放军921医院肿瘤科和湖南省肿瘤医院妇瘤科住院的卵巢癌患者201例为研究对象,采用一般资料调查问卷、创伤后成长量表、领悟社会支持量表和医学应对方式问卷对其进行调查。 结果 卵巢癌患者创伤后成长量表总分为（58.45±8.38）分,总均分为（2.78±0.40）分,处于中等水平。单因素分析显示,不同居住地、宗教信仰、文化程度、家庭月收入、是否合并慢性疾病、病程的卵巢癌患者创伤后成长量表得分差异有统计学意义（P＜0.05）。Pearson相关分析显示创伤后成长与领悟社会支持呈正相关;与医学应对方式中的面对应对和回避应对呈正相关,与屈服应对呈负相关（P＜0.05）。多元线性回归分析发现领悟社会支持、面对应对、回避应对是卵巢癌患者创伤后成长的主要影响因素,可解释总变异的89.70%。 结论 卵巢癌患者创伤后成长处于中等水平,护理人员应根据创伤后成长影响因素,制定针对性的干预措施,促进患者尽快从疾病创伤中恢复。     

卵巢癌早期诊断及治疗分析

目的探讨卵巢癌的早期诊断和治疗方法。方法回顾性分析68例早期卵巢癌患者的临床资料。结果所有患者都顺利通过手术或内科治疗过程后,出院后经随访,5年生存率达76.5%。结论卵巢癌的早期诊断对卵巢癌的预后影响很大,其主要的治疗手段是手术和化疗。     

结肠癌患者血清IL-8与抗凋亡基因Bcl-2、促凋亡基因Bax的相关性研究

目的探讨结肠癌患者血清白细胞介素8(IL-8)与抗凋亡基因Bcl-2、促凋亡基因Bax的关系。方法检测不同分期结肠癌患者血中的IL-8、肿瘤组织中的抗凋亡基因Bcl-2以及促凋亡基因Bax的表达,并分析其中可能存在的关系。结果 C、D期患者血清IL-8、Bcl-2含量明显高于A、B期,D期患者IL-8含量明显高于C期;D期患者中Bax含量明显低于A、B、C三期患者,同时C期患者Bax含量明显低于A患者,但与B期患者无明显差异。相关性分析发现,IL-8与Bcl-2呈显著正相关,而与Bax呈显著负相关。结论 IL-8可能通过升高Bcl-2表达,同时抑制Bax的表达,使细胞凋亡受到影响,从而促进了结肠癌的进展。     

口服来曲唑对绝经后乳腺癌患者血清血管内皮生长因子的影响

目的通过测定绝经后女性乳腺癌患者口服来曲唑治疗前、后血清血管上皮生长因子(VEGF)的浓度变化,观察血清VEGF与绝经后乳腺癌患者来曲唑疗效之间的相关性。方法采用酶联免疫吸附法(ELISA)分别检测49例绝经后乳腺癌患者来曲唑治疗前、治疗1年后血清VEGF水平,并以33名正常健康志愿者血清VEGF水平作为对照。结果 49例绝经后乳腺癌患者服药前血清VEGF水平明显高于对照组(P<0.01),服用来曲唑治疗1年后血清VEGF显著下降(P<0.01),且ER(+)患者血清VEGF下降程度显著高于ER(-)患者(P<0.01)。结论口服来曲唑治疗绝经后女性乳腺癌患者血清VEGF表达下降,有助于预防乳腺癌复发和转移。     

严重脓毒症患者血管内皮生长因子水平及其与预后的关系

目的 通过检测严重脓毒症患者血清血管内皮生长因子(vascttlar endothelial growth Factor,VEGF)水平,探讨其与疾病严重程度及预后的关系.方法 采用对照研究方法,收集2006-07-2007-11期间天津医科大学第二医院ICU收治的严重脓毒症病例,根据28 d转归分为生存组和死亡组,对照组为健康人,严重脓毒症患者均于发病后1,3,7 d检测血常规、血气分析、血生化、G-反应蛋白、乳酸,计算APACHE Ⅱ评分,采用ELISA方法检测血清VEGF水平,统计学分析计量资料采用F检验,相关分析用spearman相关系数,死亡危险因素筛选采用Logistic回归分析.结果 共入选病例29例,生存16例,死亡13例,对照31例,对照组VECF为(78.77 4±8.15)pg/mL,生存组1,3,7 d VEGF为(210.47±59.40)pg/mL,(161.79±32.58)pg/mL,(85.33±12.13)pg/mL,其峰值出现在第1天,随病程进展VEGF逐渐下降,第7天与对照组比较差异无统计学意义(P>0.05);死亡组1,3,7 d VEGF为(324.12±44.35)pg/mL,(185.40±30.92)pg/mL,(273.32±55.23)pg/mL,其峰值亦出现在第1天,随病程进展第7天VEGF下降不明显,与对照组比较差异有统计学意义(P<0.01),VEGF与APACHE Ⅱ评分呈正相关(rs=0.510,P<0.01),均为影响预后的死亡危险冈素.结论 严重脓毒症患者VEGF水平在发病早期升高,其与APACHEⅡ评分有显著的相关性,是影响预后的死亡危险因素之一.